The current financial score of Corcept Therapeutics Inc is 8.79. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 256.15M, representing a year-over-year increase of 31.74%, while its net profit experienced a year-over-year increase of 22.30%.
The current valuation score of Corcept Therapeutics Inc is 7.15. Its current P/E ratio is 250.80, which is 7.58% below the recent high of 269.82 and 92.28% above the recent low of 19.35.
The current earnings forecast score of Corcept Therapeutics Inc is 7.33. The average price target is 138.81, with a high of 165.00 and a low of 50.00.
The current price momentum score of Corcept Therapeutics Inc is 3.82. Currently, the stock price is trading between the resistance level at 124.75 and the support level at 106.61, making it suitable for range-bound swing trading.
The current institutional shareholding score of Corcept Therapeutics Inc is 7.00. The latest institutional shareholding proportion is 71.62%, representing a quarter-over-quarter decrease of 14.25%. The largest institutional shareholder is James Simons, holding a total of 5.26M shares, representing 0.63% of shares outstanding, with 40.67% decrease in holdings.
The current risk assessment score of Corcept Therapeutics Inc is 4.67. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.